Preparation and pharmaceutical application of a novel pentacyclic triterpenoid
The novel pentacyclic triterpenoid compound 2CH2LA addresses the limitations of existing cancer treatments by demonstrating potent anticancer activity against resistant cancer types with minimal side effects, effectively inhibiting cancer cell growth and metastasis in preclinical models.
Patent Information
- Application Number
- PCT/IN2024/050255
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-03-22
- Filing Date
- 2024-03-12
- Publication Date
- 2024-11-14
AI Technical Summary
Current cancer chemotherapeutics face limitations such as severe side effects and resistance, necessitating the development of new anticancer drugs with improved efficacy and minimal side effects.
A novel pentacyclic triterpenoid compound, 2CH2LA, derived from Lantadene A, is synthesized and evaluated for its anticancer and anti-inflammatory properties, demonstrating potent activity against kidney cancer cell lines and resistance cancers through various in vitro and in vivo assays.
2CH2LA exhibits strong cytotoxic effects, inhibits cancer cell growth, and reduces metastatic abilities, showing significant anticancer activity with minimal toxicity in preclinical models, including renal cell carcinoma and anti-androgen-resistant prostate cancer cells.
Smart Images

Figure IMGF000002_0001 
Figure 00000009_0000 
Figure 00000010_0000
Abstract
Description
[0001] Description
[0002] Title of Invention: Preparation and pharmaceutical application of a novel pentacyclic triterpenoid
[0003] Cross-reference to related applications This application claims the benefit of priority to Indian application No. IN202321019822, filed March 22, 2023, which is incorporated by reference herein in its entirety.
[0004] Field of the invention The present invention relates to the preparation and pharmaceutical use of a compound of formula I and its pharmaceutically acceptable salts, solvates, stereoisomers, and crystalline and amorphous forms in cancer, inflammation, autoimmune diseases, and oxidative-stress- associated diseases, including kidney and eye injuries.
[0005] Compound of formula I (2CH2LA)
[0006] Background of the invention Cancer is a malignant disease that manifests in neighboring and distant tissues via the blood and lymphatic system. It is the second-leading cause of death worldwide accounting for around 9.6 million deaths in 2018 [1], Despite advances in treatment, cancer continues to exert a great financial, physical, and emotional burden on patients, families, and healthcare systems. Early detection and effective treatment of cancer not only increase the chances of a patient's survival but also lessen the economic burden. The treatment strategy for cancer involves surgery, radiation therapy, and chemotherapeutics. The existing cancer chemotherapeutics suffer from several limitations, including severe adverse and side effects and resistance to treatment. Thus, there is an unmet medical need for new anticancer drugs with efficacy against resistance cancers while imparting minimal side effects. Lantadenes are pentacyclic triterpenoids obtained from the leaves of the weed Lantana camara Linn. These pentacyclic triterpenoids are chemically related to the oleanane series of triterpenoids. In the past, oleanolic acid and structurally related triterpenoids, including Lantadenes have been explored for various biological indications. However, none of these natural products or their derivatives have progressed to the clinics. Lantadene A, which is abundantly present in the Lantana leaves is a weak anticancer compound (Fig. 1). It differs from
[0007] SUBSTITUTE SHEET (RULE 26) oleanolic acid that it has an angeloyloxy side chain at the C-22 position while at the C-3 position, it bears a carbonyl group instead of the hydroxyl group in oleanolic acid. In search of a novel and potent anticancer compound, we synthesized several Lantadene A (here forward will be referred to as LA at some places) derivatives and evaluated them against various types of cancer cells. Our preliminary anticancer screening provided a compound of formula I, here forward will be referred to as 2CH2LA, potently active against kidney cancer cell lines. We further established the anticancer and anti-inflammatory efficacy of the compound through various in vitro and in vivo assays.
[0008] Description of the related prior art US patent US-20030119732-A1 describes the preparation and use of pentacyclic triterpenoids of the oleanane series for the treatment of cancers. US patent US-20090048204-A1 describes the synthesis of oleanolic acid analogs with improved bioavailability for treating inflammatory diseases. US patent US-20080261985-A1 accounts for the synthesis of oleanolic acid analogs for the treatment of cancer, inflammation, neurological diseases, and oxidative stress conditions. US patent US-20090060873-A1 details the synthesis and use of pentacyclic triterpenoids against neurodegenerative and psychiatric diseases and disorders. US patents US-20090326063-A1 and US-8455544-B2 mention the synthesis of pentacyclic triterpenoids for the treatment of renal and kidney diseases, insulin resistance diabetes, fatty liver diseases, endothelium diseases, and cardiovascular diseases. US patents US-8071632-B2, US-8338618-B2, US-20210040142-A1, US-10898499-B2, US- 20200129530-A1, and US-11406648-B2 describe oleanolic acid derivatives for applications in cancer, inflammation, neurological diseases, and in oxidative stress. US patent US-20190125715-A1 mentions using oleanolic acid derivative CDDO-Me to treat lupus and autoimmune diseases. US patents US-20190350941-A1, US-20210161914-A1, US-10953020-B2, and US-11446313-B2 detail the synthesis of oleanolic acid derivatives for the treatment of Alport syndrome- associated kidney disease. US patent US-8299046-B2 describes oleanolic acid derivatives for use in stimulating bone and cartilage growth JP2008247898A describes pentacyclic triterpenoids of the oleanane series for the treatment of oxidative stress-associated eye injury.
[0009] A brief description of the drawings Fig. 1. Chemical structure of oleanolic acid and Lantadene A. Fig. 2. Chemical synthesis of the compound of formula I (2CH2LA) from Lantadene A (LA).
[0010] SUBSTITUTE SHEET (RULE 26) Fig. 3. Percent cell viability of different cancer cell lines following treatment with the 2CH2LA. Fig. 4. (A) Dose course of cell viability was measured for the indicated cell lines using MTS / PES cell titer assay. (B) Morphological evaluation of 786-0 cells treated with indicated doses (pM) of 2CH2LA for 72 h. The photographs were taken under a phase-contrast microscope. Fig. 5. Soft agar assay of 786-0 and pcENZRcells treated with indicated doses of 2CH2LA for 21 days. Fig. 6. (A) The effect of 2CH2LA on the migration of 786-0 cells (wound healing), wherein cells plated at 90-100% confluency were subjected to the scratch test. The wound closure rate over 24 h was observed. (B) The effect of 2CH2LA on the in-vitro invasive capability of 786-0 cells using the Boyden chamber assay. Fig. 7. Analysis of 2CH2LA-induced apoptotic DNA fragmentation in indicated cells using an ELISA kit (Roche). Fig. 8. Effect of 2CH2LA on renal cell carcinoma xenograft model. Tumor volumes were measured by Vernier calipers. Fig. 9. The effect of 2CH2LA treatment on oxidative stress and inflammation marker genes / proteins.
[0011] A detailed description of the invention The invention is illustrated with exemplary embodiments in the following, which however should not be constructed as being limited to the exemplary embodiments of the present invention.
[0012] Examples Example 1. Chemical synthesis of the invented compound of formula I
[0013] 2CH2LA; 2-Methylene-3-oxo-226-angeloyloxy-olean-12-en-28-oic acid (Fig. 2) To a 27 mg (0.05 mol) of Lantadene A in 1 ml of dry dimethylformamide (DMF) in a glass container were added 4 equivalents of potassium carbonate (K2CO3), and 5 equivalents of paraformaldehyde (OH(CH2O)nH). The reaction mixture was stirred for 7 hours at 85 °C. The reaction mixture was neutralized with 10% hydrochloric acid (HCI) and extracted with dichloromethane. Dichloromethane was removed under a rotary evaporator to give the crude product. The crude product was finally purified using acetonitrile-water as an eluent in preparative HPLC on the C18 column. Yield: 18 mg (65%); color: white;XH NMR (600 MHz, CDCI3, 6) ppm: 6.01-6.05 (2H, m, C-2'-Ha & C-33-H merged), 5.43 (1H, t, J = 3.4 Hz, C-12-H), 5.18 (1H, s, C-2'-Hb), 5.12 (1H, t, J = 3.1 Hz, C- 22-H), 3.07-3.10 (1H, dd, J = 13.4 & 3.7 Hz, C-18-H), 1.99 (CH^), 1.80 (CH^), 1.26 (CH^), 1.14 (CH3), 1.07 (CH3), 1.03 (CH3), 0.95 (CH3), 0.91 (CH^), 0.85 (CH^).13C HSQC NMR (151 MHz, CDCI3, 6) ppm: 139.0 (C-33), 123.8 (C-2'), 122.5 (C-12), 75.8 (C-22), 38.7 (C-18);13C HMBC NMR (151 MHz, CDCI3, 6) ppm: 168.8 (C-31), 145.6 (=CH2-C- or C-2), 144.4 (C-13), 130.2 (C-32).
[0014] SUBSTITUTE SHEET (RULE 26) Example 2. Demonstration of the effectiveness of the invented compound
[0015] MTS cell viability assay To examine the anticancer potential of 2CH2LA and parent compound Lantadene A (LA), a wide variety of human cancer-derived cell lines representing different tumor types (Fig. 3 and Fig. 4) were used. For cell viability evaluation, cancer cells (3,000 cells per well) were plated in 96-well plates in a complete growth medium (RPMI or DMEM plus 10% FBS) and treated with a single dose (10 pM) of 2CH2LA or LA. Plates were incubated for 48 hours at 37 °C in a CO2incubator. Cell viability was measured by MTS / PES cell titer assay (Promega Corp., Madison, Wl) by adding 20 pl of CellTiter 96® AQueous One Solution Reagent into each well of the 96-well assay plate containing the samples in 100 pl of culture medium. The plates were incubated at 37 °C in a CO2incubator for 1 hour and the absorbance was recorded at 490 nm using a 96-well plate reader. Among the screened cell lines, 2CH2LA showed strong cytotoxic effects against renal cancer cells (RCC) and anti-androgen (AR) therapy-resistant prostate cancer cells (PCENZR) compared to the parent compound, LA (Fig. 3). Furthermore, 2CH2LA inhibited the growth of RCC and pcENZRcells in a dose-dependent manner (Fig. 4). Example 3. Demonstration of the effectiveness of the invented compound
[0016] Soft-agar colony formation assay of cancer cells The effect of 2CH2LA on soft-agar colony formation was also analyzed (Fig. 5). 786-0 (hypertriploid RCC cells) and PCENZRcells (10,000 per well in 6-well plates) were plated in 0.35% soft-agar on top of a base layer of 0.7% agar. The cells were treated with 2CH2LA and incubated at 37 °C for three weeks in the CO2incubator. Cells were given fresh media and compound every fourth day. At the end of the incubation period, colonies were stained with 0.025% crystal violet, and photographs of colonies were taken with a digital camera attached to a Leica microscope at x200. 2CH2LA at 4pM completely blocked soft-agar colony formation (Fig. 5). 2CH2LA elicited the degradation of chromatin DNA to nucleosomal fragments in 786-0 and pcENZRcells in a dosedependent manner (Fig. 5), suggesting that 2CH2LA kills 786-0 and PCENZRcells via apoptosis. Example 4. Demonstration of the effectiveness of the invented compound
[0017] Cell migration and invasion assays of cancer cells Cell migration assay: To test the effect of 2CH2LA on cell migration, the scratch assay was performed on 786-0 cells. The scratch was created by scraping the cells' monolayer in a straight line with a p200 pipet tip. The debris was removed, and cells were washed with 1 ml of the growth medium and then replaced with 5 ml of medium with or without 2CH2LA. The plates were placed in a tissue culture incubator at 37 °C for 12-24 h. The scratch photographs were taken under a phase-contrast microscope at different time points. 2CH2LA at 4 pM notably decreases the migration capacity of renal carcinoma cells (Fig. 6A). Invasion assay: To test the effect of 2CH2LA on cell invasion, in vitro invasion assay was performed using Matrigel-coated Boyden transwell chambers. Chambers were soaked in 50 pl
[0018] SUBSTITUTE SHEET (RULE 26) serum-free medium for 30 minutes at room temperature and then 50,000 cells were added to each 24-well invasion chamber. These chambers were then placed in a 24-well plate on top of 500 pl chemoattractant (RPMI medium containing 3% fetal bovine serum) with or without 2CH2LA. The cell invasion chambers were incubated overnight in a humidified tissue culture incubator at 37 °C, 5% CO2atmosphere. Non-invaded cells from the apical side were scrapped with a cotton swab, membranes were fixed in methanol, and stained with 0.025% crystal violet. The invaded cells were observed under the microscope. 2CH2LA decreases the Matrigel-invasive capacity of renal carcinoma cells (786-0) in a dose-dependent manner suggesting that the metastatic abilities of these cells could be significantly inhibited by 2CH2LA treatment (Fig. 6B). 8 Example 5. Demonstration of the effectiveness of the invented compound
[0019] Apoptotic DNA degradation assay of cancer cells 9 To test the effect of 2CH2LA on cancer cell apoptosis, 786-0 and pcENZRcells were treated with 2CH2LA for 24 hours. The cell lysates were used for measuring DNA degradation to nucleosomal fragments, a read-out for apoptosis, using an ELISA kit from Roche (St. Louis, MO) following the kit protocol. 2CH2LA showed strong apoptotic effects (DNA fragmentation) against renal cell cancer (RCC) cells and anti-androgen (AR) therapy-resistant prostate cancer cells (PCENZR) (Fig. 7). 0 Example 6. Demonstration of the effectiveness of the invented compound
[0020] 2CH2LA inhibits renal cell carcinoma (RCC) growth in nude mice 1 To investigate the antitumor effects of 2CH2LA in vivo, exponentially growing 786-0 cells (2 x 10scells / mouse in 50% Matrigel in PBS) were subcutaneously injected into the right flanks of 7- week-old athymic nude mice. When the tumors grew to approximately 100 mm3, mice were randomized and treated with vehicle or 2CH2LA (5 mg / kg / day) intraperitoneally for 4 weeks. Tumor size and mice body weights were measured once per week. Tumor growth was monitored by measuring volumes using a digital slide-caliper. Tumor volumes (TV) were calculated by the formula TV = % (Length x Width2). 2CH2LA inhibits RCC tumor growth in nude mice without any overt toxicity to animal health (Fig. 8). These findings suggest that 2CH2LA is a suitable compound with excellent in vivo effects. 2 Example 7. Demonstration of the effectiveness of the invented compound
[0021] Effect of 2CH2LA treatment on oxidative stress and inflammation markers 3 To analyze the effect of 2CH2LA treatment on oxidative stress and inflammation markers, 786-0 (renal cell carcinoma) cells were treated with 2CH2LA for 24 hours, and the mRNA and protein levels were analyzed. 4 For RNA analysis, total RNA was extracted from 786-0 cells using TRIzol reagent, and 1 pg of total RNA was used for cDNA synthesis using the Superscript III First-Strand kit (Invitrogen) according to the manufacturer's instructions. RNA sequencing was performed using the Illumina NovaSeq platform by Novogene, China.
[0022] SUBSTITUTE SHEET (RULE 26) For protein analysis, the cells were lysed using urea-based protein lysis buffer with sonication at 30% power for 3 times with 2 seconds on and 5 seconds off cycles, and the total protein was quantified with the Bradford protein assay. The analysis of differentially expressed proteins between groups was conducted using Label-Free Quantitative Proteomic Analysis conducted by Novogene, China. The effects of 2CH2LA on the mRNA and protein levels of oxidative stress and inflammation markers in the cancer cells are shown as a fold change compared to the control group (Fig. 9).
[0023] References WHO (World Health Organization). Cancer. Available on: https: / / www.who.int / health- topics / cancer#tab=tab_l (accessed on 2 March 2023).
[0024] SUBSTITUTE SHEET (RULE 26)
Claims
Claims
1. We claim the method of preparation of the compound of formula I (2CH2LA) from Lantadene A (LA) a. Where the starting material is natural or synthetic Lantadene A or a chemical scaffold or pharmacophore of Lantadene A b. Where paraformaldehyde or formaldehyde is used as a reactant or a reagent c. Where the base is used but not limited to K2CO3d. Where DMF is used as a solvent but not limited to DMF
2. We claim the chemical structure of the compound of formula I, including its stereoisomers, pharmaceutically acceptable salts, solvates, and crystalline and amorphous forms.
3. We claim the pharmaceutical and medical use of the compound of formula I, including its stereoisomers, pharmaceutically acceptable salts, solvates, and crystalline and amorphous forms for the treatment of all types of cancers, including drug-resistant cancers.
4. We claim the pharmaceutical and medical use of the compound of formula I, including its stereoisomers, pharmaceutically acceptable salts, solvates, and crystalline and amorphous forms for the treatment of inflammation, inflammatory diseases, and oxidative stress-associated diseases, including but not limited to autoimmune diseases, renal inflammation and injury, and eye inflammation and injury.SUBSTITUTE SHEET (RULE 26)
